Dr Gunnel Halldén
Academic
Research
oncolytic virus, prostate cancer, pancreatic cancer
Interests
virology, adenovirus, cell killing modes, novel therapeuticsPublications
2021
Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacyGonzalez-Pastor R, Hernandez Y, Gimeno M, de Martino A, Man YKS, Hallden G, Quintanilla M, de la Fuente JM and Martin-Duque P
Acta Biomaterialia vol. 134, 593-604.
15-10-2021
2019
Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancerStella Man YK, Foster J, Carapuça E, Davies JA, Parker AL, Sosabowski J and Halldén G
Scientific Reports, Springer Nature vol. 9 (1)
06-09-2019
ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPYHallden G, Wang Y, Wong H-H and Lemoine NR
In Advanced Textbook On Gene Transfer, Gene Therapy and Genetic Pharmacology 323-345.
17-07-2019
2018
Advances in oncolytic adenovirus therapy for pancreatic cancerNattress CB and Halldén G
Cancer Letters vol. 434, 56-69.
10-10-2018
Designer oncolytic adenovirus: Coming of ageBaker AT, Aguirre-Hernández C, Halldén G and Parker AL
Cancers vol. 10 (6)
14-06-2018
The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cellsMan YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL and Halldén G
Molecular Cancer Therapeutics vol. 17 (2), 575-587.
01-02-2018
Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus AdΔΔ through Bcl-2-dependent attenuation of autophagyAguirre-Hernández C, Maya-Pineda H, Millán JS, Man YKS, Lu YJ and Halldén G
Oncogenesis vol. 7 (1)
01-01-2018
2017
Targeting pancreatic and prostate cancer with E1B19K-deleted oncolytic adenovirusesHallden G
01-08-2017
2016
The adenoviral Ad Delta Delta mutant enhances mitoxantrone-induced apoptosis and attenuates drug-induced autophagy in prostate cancer cells.Aguirre-Hernandez C, Millan JS and Hallden G
01-11-2016
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11Pantelidou C, Cherubini G, Lemoine NR and Halldén G
Oncotarget vol. 7 (13), 15703-15724.
29-03-2016
Oncolytic adenovirus-mediated therapy for prostate cancer.Sweeney K and Halldén G
Oncolytic Virother vol. 5, 45-57.
01-01-2016
Oncolytic adenoviral mutants deleted in the anti-apoptotic E1B19K gene sensitize pancreatic cancer cells to drug-induced DNA damagePantelidou C, Man YKS, Coughlan L, Marshall J, Kocher H and Hallden G
International Journal of Molecular Medicine vol. 38, S58-S58.
01-01-2016
2014
18: ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPYHallden G, Wang Y, Wong H-H and Lemoine NR
In Advanced Textbook On Gene Transfer, Gene Therapy and Genetic Pharmacology 307-329.
14-01-2014
2013
Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells.Passaro C, Abagnale A, Libertini S, Volpe M, Botta G, Cella L, Pacelli R, Halldèn G, Gillespie D and Portella G
Endocr Relat Cancer vol. 20 (5), 633-647.
01-10-2013
2012
Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.Halldén G and Portella G
Expert Opin Ther Targets vol. 16 (10), 945-958.
01-10-2012
Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models.Adam V, Ekblad M, Sweeney K, Müller H, Busch KH, Johnsen CT, Kang NR, Lemoine NR and Halldén G
Hum Gene Ther vol. 23 (9), 1003-1015.
01-09-2012
Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo.Botta G, Passaro C, Libertini S, Abagnale A, Barbato S, Maione AS, Hallden G, Beguinot F, Formisano P and Portella G
Hum Gene Ther vol. 23 (6), 623-634.
01-06-2012
Abstract 2712: A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cellsSweeney KG, Cheong SC, Lemoine NR and Hallden G
, 2712-2712.
15-04-2012
Abstract 2713: Adenovirus E1A binding to p300 is essential for synergistic cell killing in combination with chemotherapeutic drugs in prostate cancer cellsMaya-Pineda HR, Miranda-Rota E, Lemoine NR and Halldén G
, 2713-2713.
15-04-2012
Adenoviral gene expression and replication in human tumor explant models.Halldén G
Methods Mol Biol vol. 797, 65-78.
01-01-2012
Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.Miranda E, Maya Pineda H, Öberg D, Cherubini G, Garate Z, Lemoine NR and Halldén G
Plos One vol. 7 (10)
01-01-2012
2011
The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models.Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Müller H, Lemoine NR and Halldén G
Gene Ther vol. 18 (12), 1157-1165.
01-12-2011
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR and Halldén G
Cancer Gene Ther vol. 18 (10), 734-743.
01-10-2011
Adenovirus sensitizes pancreatic cancer cells to DNA-damaging chemotherapeutics through mitotic catastrophe induction and this is further enhanced by the deletion of the anti-apoptotic E1B19K genePantelidou C, Cherubini G, Lemoine NR and Hallden G
Human Gene Therapy vol. 22 (10), A119-A120.
01-10-2011
A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cellsSweeney K, Cheong SC, Lemoine N and Hallden G
Human Gene Therapy vol. 22 (10), A122-A122.
01-10-2011
Adenovirus CIA binding to p300 is essential for synergistic cell killing in combination with chemotherapeutics in prostate cancer cellsMaya-Pineda H, Miranda E, Lemoine N and Hallden G
Human Gene Therapy vol. 22 (10), A104-A104.
01-10-2011
2010
Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer.Ingemarsdotter CK, Baird SK, Connell CM, Öberg D, Halldén G and McNeish IA
Oncogene vol. 29 (45), 6051-6063.
11-11-2010
Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR and Halldén G
Hum Gene Ther vol. 21 (10), 1311-1325.
01-10-2010
Adenovirus-based therapy for prostate cancer.Ekblad M and Halldén G
Curr Opin Mol Ther vol. 12 (4), 421-431.
01-08-2010
Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR and Halldén G
Clin Cancer Res vol. 16 (2), 541-553.
15-01-2010
2009
P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion.Lee M, Choi S, Halldén G, Yo SJ, Schichnes D and Aponte GW
Am J Physiol Gastrointest Liver Physiol vol. 297 (4), G641-G654.
01-10-2009
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeuticsHallden G
J Buon vol. 14, S61-S67.
01-09-2009
Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR and Halldén G
Clin Cancer Res vol. 15 (5), 1730-1740.
01-03-2009
2008
Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus d/922-947Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R, Hallden G and Portella G
Clin Cancer Res vol. 14 (20), 6505-6514.
15-10-2008
Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V, Shen Y and Seymour LW
Hum Gene Ther vol. 19 (9), 873-886.
01-09-2008
Comparison of Molecular Strategies for Breast Cancer Virotherapy using Oncolytic Adenovirus.Seymour LW, Bazan-Peregrino M, Carlisle R, Hernandez-Alcoceba R, Iggo R, Homicsko K, Hallden G, Mautner V, Shen J and Fisher K
Hum Gene Ther
27-06-2008
E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.Cheong SC, Wang Y, Meng J-H, Hill R, Sweeney K, Kirn D, Lemoine NR and Halldén G
Cancer Gene Ther vol. 15 (1), 40-50.
01-01-2008
2007
Lysis of dysplastic but not normal oral keratinocytes and tissue-engineered epithelia with conditionally replicating adenovirusesGaballah K, Hills A, Curiel D, Hallden G, Harrison P and Partridge M
Cancer Res vol. 67 (15), 7284-7294.
01-08-2007
GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cellsChoi S, Lee M, Shiu AL, Yo SJ, Hallden G and Aponte GW
Am J Physiol-Gastr L vol. 292 (5), G1366-G1375.
01-05-2007
2006
Oncolytic virotherapy for nasopharyngeal cancerBapat U, Wang Y, Alusi G, Chisholm E, Francis J, Hallden G and Lemoine N
Clinical Otolaryngology vol. 31 (6), 582-583.
01-12-2006
2005
Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.Liu T-C, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR and Kirn D
Gene Ther vol. 12 (17), 1333-1346.
01-09-2005
Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors.Wang Y, Xue S-A, Hallden G, Francis J, Yuan M, Griffin BE and Lemoine NR
Cancer Res vol. 65 (4), 1523-1531.
15-02-2005
Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activity.Lee M, Hadi M, Halldén G and Aponte GW
J Biol Chem vol. 280 (1), 125-136.
07-01-2005
A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D and Halldén G
Clin Cancer Res vol. 11 (1), 351-360.
01-01-2005
2004
Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite.Wang Y, Faux SP, Hallden G, Kirn DH, Houghton CE, Lemoine NR and Patrick G
Int J Oncol vol. 25 (1), 173-178.
01-07-2004
An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency.Liu T-C, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N and Kirn D
Mol Ther vol. 9 (6), 786-803.
01-06-2004
Replication-selective oncolytic adenoviruses.Halldén G, Thorne SH, Yang J and Kirn DH
Methods Mol Med vol. 90, 71-90.
01-01-2004
2003
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.Wang Y, Hallden G, Hill R, Anand A, Liu T-C, Francis J, Brooks G, Lemoine N and Kirn D
Nat Biotechnol vol. 21 (11), 1328-1335.
01-11-2003
Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.Halldén G, Hill R, Wang Y, Anand A, Liu T-C, Lemoine NR, Francis J, Hawkins L and Kirn D
Mol Ther vol. 8 (3), 412-424.
01-09-2003
2002
The emerging fields of suicide gene therapy and virotherapy.Kirn D, Niculescu-Duvaz I, Hallden G and Springer CJ
Trends Mol Med vol. 8 (4 Suppl), S68-S73.
01-01-2002
1994
Expression of intestinal fatty acid binding protein in intestinal epithelial cell lines, hBRIE 380 cellsHallden G, Holehouse EL, Dong X and Aponte GW
American Journal of Physiology - Gastrointestinal and Liver Physiology vol. 267 (4 30-4)
01-01-1994
1989
Trophic effect of amniotic fluid on cultured fetal gastric mucosal cellsMulvihill SJ, Hallden G and Debas HT
Journal of Surgical Research vol. 46 (4), 327-329.
01-01-1989
Purification of the pancreatic cholecystokinin receptorSzecowka J, Hallden G, Goldfine ID and Williams JA
Regulatory Peptides vol. 24 (3), 215-224.
01-01-1989
Grants
Identification of drugs that promote activation of the host anticancer immune-responses through enhancement of virus-mediated cell lysisGunnel Halldén
£199,906 PCRF Pancreatic Cancer Research Fund
01-12-2018 - 15-12-2022